137 completed, 81 unknown, 64 terminated, 37 withdrawn. 332 Phase 2, 61 Phase 3, 57 Phase 1.
Follow Covid19: new trials by email Literature Review of Covid19 trials Research Report on Covid19
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Direct Topical Lung T3 Treatment to Improve Outcome & Sequelae of COVID-19 Acute Respiratory Distress Syndrome Instilled T3, Placebo Therapy - Covid19, SARS-CoV Infection | Phase 2 | Withdrawn | University of Minnesota | 2026-01-15 | 2026-02-10 | |
| "Efesovir" (FS-1) for COVID-19, Phase 2 Efesovir - Covid19 | Phase 2 | Not yet recruiting | Scientific Center for Anti-infectious Drugs, Kazakhstan | 62 | 2025-12-01 | 2024-04-17 |
| ExoFlo™ Infusion for Post-Acute COVID-19 and Chronic Post-COVID-19 Syndrome Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles, Saline - Covid19, Postviral Syndrome | Phase 1 / Phase 2 | Withdrawn | Direct Biologics, LLC | 2024-11-01 | 2024-11-22 | |
| Clinical Study for Subjects With COVID-19 Using Allogeneic Adipose Tissue-Derived Mesenchymal Stem Cells Allogeneic adipose-derived stem cells - Corona Virus Infection, Covid19 | Phase 2 | Not yet recruiting | Celltex Therapeutics Corporation | 30 | 2024-11-01 | 2024-02-07 |
| NAC for Attenuation of COVID-19 Symptomatology N-acetylcysteine, Placebo - Covid19, COVID-19 Pneumonia | Phase 2 | Unknown | Cambridge Health Alliance | 200 | 2024-03-31 | 2023-08-07 |
| Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells to Treat Post COVID-19 "Long Haul" Pulmonary Compromise COVI-MSC, Placebo - Covid19 | Phase 2 | Withdrawn | Sorrento Therapeutics, Inc. | 2024-02-01 | 2024-04-17 | |
| SLV213 Treatment in Ambulatory COVID-19 Patients SLV213, Placebo - Covid19 | Phase 2 | Unknown | Kenneth Krantz, MD, PhD | 81 | 2023-11-01 | 2023-04-12 |
| COVID-19 ThromboprophylaXIs Study of Novel FXIa Inhibitor Frunexian (EP-7041) in ICU Patients EP-7041 Injection - Thrombopenia, Covid19 | Phase 2 | Withdrawn | eXIthera Pharmaceuticals | 2023-10-01 | 2023-10-05 | |
| The Use of Exosomes for the Treatment of Acute Respiratory Distress Syndrome or Novel Coronavirus Pneumonia Caused by COVID-19 MSC-exosomes delivered intravenously every other day on an escalating dose: (2:4:8), MSC-exosomes delivered intravenously every other day on an escalating dose (8:4:8), MSC-exosomes delivered intravenously every other day (8:8:8) - Covid19, Novel Coronavirus Pneumonia | Phase 1 / Phase 2 | Unknown | AVEM HealthCare | 55 | 2023-09-01 | 2022-03-11 |
| Leidos-Enabled Adaptive Protocol for Clinical Trials (LEAP-CT) in Hospitalized Patients With COVID-19 (Addendum 1) Famotidine, Celecoxib, Placebo - 2019 Novel Coronavirus Disease, 2019 Novel Coronavirus Infection | Phase 2 | Withdrawn | Leidos Life Sciences | 2023-02-07 | 2023-10-10 | |
| Study Designed to Evaluate the Effect of CimetrA in Patients Diagnosed With COVID-19 Biochemistry blood test, Hematology blood test, D-Dimer test (coagulation) - Covid19, Corona Virus Infection | Phase 2 | Completed | MGC Pharmaceuticals d.o.o | 240 | 2022-10-11 | 2023-03-15 |
| In-patient COVID-19 Study of Intranasal Foralumab Foralumab, Placebo - Covid19, COVID-19 Lower Respiratory Infection | Phase 2 | Withdrawn | Tiziana Life Sciences LTD | 2022-04-30 | 2022-10-19 | |
| COVID-FIS: Pilot in COVID-19 (SARS-CoV-2) of Fisetin in Older Adults in Nursing Homes Fisetin, Placebo - Covid19, SARS-CoV Infection | Phase 2 | Terminated | Mayo Clinic | 20 | 2022-04-29 | 2025-08-26 |
| To Evaluate Safety & Immunogenicity of DelNS1-2019-nCoV-RBD-OPT1 for COVID-19 in Healthy Adults Received 2 Doses of BNT162b2 DelNS1-2019-nCoV-RBD-OPT1, Matching placebo - Covid19 | Phase 2 | Unknown | The University of Hong Kong | 150 | 2022-02-08 | 2022-10-28 |
| Evaluation of the Safety and Immunogenicity of SII Vaccine Constructs Based on the SARS-CoV-2 (COVID-19) Variant in Adults SII B.1.351, SII Bivalent, SII B.1.617.2 - Covid19 | Phase 1 / Phase 2 | Withdrawn | Novavax | 2022-02-04 | 2022-05-31 | |
| Angiotensin (1-7) for the Treatment of COVID-19 in Hospitalized Patients Angiotensin-(1-7), Placebo - Covid19 | Phase 1 / Phase 2 | Withdrawn | Stanford University | 2022-02-01 | 2022-03-03 | |
| the Safety and Efficacy of Meplazumab in Patients With COVID-19 Meplazumab for Injection, Sterile normal saline (0.9%) - Covid19 | Phase 2 / Phase 3 | Completed | Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd | 150 | 2022-01-21 | 2023-09-15 |
| Niclosamide in COVID-19 Niclosamide Oral Tablet, Placebo - Covid19 | Phase 2 | Withdrawn | Entero Therapeutics | 2022-01-20 | 2022-02-21 | |
| Leidos-Enabled Adaptive Protocol (LEAP-CT) for Evaluation of Post-exposure Prophylaxis for Newly-infected COVID-19 Patients Famotidine, Celecoxib, Placebo - 2019 Novel Coronavirus Disease, 2019 Novel Coronavirus Infection | Phase 2 | Terminated | Leidos Life Sciences | 4 | 2021-12-29 | 2024-07-09 |
| Mix and Match Heterologous Prime-Boost Study Using Approved COVID-19 Vaccines BBIBP-CorV - Inactivated SARS-CoV-2 vaccine (Vero cell), Ad26.COV2.S (Recombinant, replication-incompetent adenovirus serotype 26 (Ad26) vector encoding a full-length and stabilized SARS-CoV-2 spike protein),, Placebo - Normal saline (0.9% sodium chloride solution) - Covid19 | Phase 2 | Unknown | International Vaccine Institute | 360 | 2021-12-29 | 2023-04-19 |
Showing 20 of 332. Sign in to see all of them.
COVID-19 (332) · Coronavirus Infections (38) · Severe Acute Respiratory Syndrome (28) · Respiratory Distress Syndrome (16) · Cytokine Release Syndrome (9) · Virus Diseases (6) · Pneumonia (5) · Pneumonia, Viral (5) · Respiratory Insufficiency (5) · Anosmia (4) · Inflammation (4) · Post-Acute COVID-19 Syndrome (4) · Diabetes Mellitus (3) · Olfaction Disorders (3) · Pulmonary Fibrosis (3)
Infections (332) · Lung Diseases (332) · Respiratory Tract Diseases (332) · Coronaviridae Infections (331) · Nidovirales Infections (331) · RNA Virus Infections (331) · Respiratory Tract Infections (331) · Pneumonia (327) · Pneumonia, Viral (327) · Virus Diseases (326) · Coronavirus Infections (294) · Pathological Conditions, Signs and Symptoms (35) · Pathologic Processes (27) · Respiration Disorders (23) · Signs and Symptoms (11)
Standard of Care (15) · Ivermectin (13) · Hydroxychloroquine (12) · nitazoxanide (10) · Azithromycin (8) · camostat (7) · STI-2020 (6) · Niclosamide (5) · Sodium Chloride (5) · Famotidine (4) · Heparin (4) · Saline Solution (4) · sotrovimab (4) · BNT162 Vaccine (3) · CVnCoV COVID-19 vaccine (3)
Sorrento Therapeutics, Inc. (12) · Stanford University (5) · The University of Hong Kong (5) · Assistance Publique - Hôpitaux de Paris (4) · D'Or Institute for Research and Education (4) · Hospital do Coracao (3) · Leidos Life Sciences (3) · Maimónides Biomedical Research Institute of Córdoba (3) · Massachusetts General Hospital (3) · Ministry of Public Health, Argentina (3) · Ottawa Hospital Research Institute (3) · AgelessRx (2) · Ain Shams University (2) · Australian National University (2) · Azidus Brasil (2)
United States (105) · Brazil (28) · Argentina (17) · Canada (17) · Spain (15) · Mexico (12) · France (10) · Italy (10) · Russia (10) · United Kingdom (10) · Egypt (8) · Israel (8) · South Africa (8) · Belgium (7) · Colombia (5)
Mike Royal, MD (12) · Brian A Roberts, MS, PMP (2) · Chaitan Khosla, PhD (2) · Duncan J Stewart, MD (2) · Frank MP van Haren, MD, PhD (2) · Ivan FN Hung, MD FRCP (2) · Julie Parsonnet, MD (2) · Marcelo Silveira, MD, PhD (2) · Miriam Treggiari, MD (2) · Moneeb Ashraf, MBBS (2) · Muhammad Ashraf, PhD (2) · Patricia RM Rocco, MD, PhD (2) · Sajad Zalzala, MD (2)
PMID 34473343, PMID 31986264, PMID 32109013, PMID 32112977, PMID 32142651, PMID 32171076, PMID 32251768, PMID 35244208, PMID 35285015, PMID 35713300, PMID 36700518, PMID 36996150, PMID 37489818, PMID 10415784, PMID 11176912, PMID 11594901, PMID 12563677, PMID 12719004, PMID 14592603, PMID 14719037, PMID 15030519, PMID 15366588, PMID 15663512, PMID 15688692, PMID 15885816, PMID 1593279, PMID 15992957, PMID 16103202, PMID 16499032, PMID 17181919, PMID 17276373, PMID 17825510, PMID 18097874, PMID 18434652, PMID 18446504, PMID 18699744, PMID 18752857, PMID 19103632, PMID 19190233, PMID 19397687, PMID 19453649, PMID 19998041, PMID 2024970, PMID 20561931, PMID 21131395, PMID 21398612, PMID 21423999, PMID 22028728, PMID 22417684, PMID 22496216
1ZIDES102465 (1), R01AG064802 (1), R01AG072301 (1), U54GM104941 (1)